Epizyme, Inc. (NASDAQ:EPZM) Q1 2020 Earnings Conference Call - Final Transcript
May 04, 2020 • 09:00 am ET
Hello, and welcome to Epizyme's Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session after the prepared remarks. Please be advised that this call is being recorded at Epizyme's request.
I would now like to turn the call over to Alicia Davis. You may begin.
Thank you, and good morning. Earlier today, we issued a press release, outlining recent progress in our first quarter 2020 financial results, which can be found at epizyme.com.
On the call with me is Rob Bazemore, CEO; Matt Ros, Chief Strategy and Business Officer; Dr. Shefali Agarwal, Chief Medical Officer; and Paolo Tombesi, Chief Financial Officer who will join us for the Q&A session.
Today's discussion will include forward-looking statements related to Epizyme's current plans and expectations, which are subject to certain risks and uncertainties. Actual results may differ materially due to various important factors including those described in the Risk Factors section of our most recent Forms 10-Q, 10-K and other SEC filings. These forward-looking statements represent our views as of this call and should not be relied upon as representing our views as of any subsequent date. We undertake no obligation to publicly update these statements.
Now, let me turn the call over to Rob. Rob?
Thank you, Alicia and thank you all for joining us today. We started out the first quarter of 2020 very strong with significant progress on all of our corporate objectives. This is particularly important given the challenges that our industry has faced amidst the COVID-19 pandemic. At Epizyme, our dedication is first and foremost to the safety of patients, to the healthcare teams who provide their care, to our employees and to the communities where we live and work.
On behalf of the entire organization, I would like to extend our sincerest gratitude to the treatment centers, medical professionals, caregivers and all of those on the front-line working to keep us safe. Their commitment is truly an inspiration. Despite the many uncertainties that have been created by this pandemic, we know that people with cancer and other serious diseases are also still in need of new treatment options and we remain focused on maximizing the clinical and commercial potential of TAZVERIK, further strengthening our ability to impact patients' lives and create long-term value.
Last quarter, we activated business continuity plans that were designed to allow us to maintain our momentum commercializing TAZVERIK and advancing our clinical programs and our early pipeline, while minimizing disruptions to our business and ensuring the safety and well-being of our team, their families and our collaborators. We've not lost sight of our mission and we continue to evaluate the situation on an ongoing basis assessing the many uncertainties and potential impact that this could have on our business and we will adjust our plans accordingly. In early March, we shifted the entire company to a remote operating model except for a small number of essential labs and facilities personnel, who have been working on